Fundraising FoxInflammasome Therapeutics
Newton, US · Delaware corporation
Find your way into Inflammasome Therapeutics
Sign up to see every warm intro you have to Inflammasome Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Inflammasome Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Inflammasome Therapeutics develops treatments for degenerative diseases including Alzheimer's disease, multiple sclerosis, macular degeneration, and Parkinson's disease. Its approach targets inflammasome activation as a mechanism to treat these conditions.
Founders & leadership
PA
Paul AshtonCo-founderPaul Ashton served as CEO of a NASDAQ-listed biopharmaceutical company for 7 years, where he oversaw development of sustained-release treatments for back-of-the-eye diseases and secured major pharma collaborations. He is a recognized researcher in ophthalmology and drug delivery with over 200 peer-reviewed publications and 120+ U.S. and international patents.
JA
Jayakrishna AmbatiCo-founder
Board
BA
Balamurali AmbatiBoard director
JL
Joon LeeBoard director
NF
Napoleone FerraraBoard director
MW
Mary WeberBoard director
Reported raises · per SEC filings
Form D private placements$19.4M disclosed across 3 rounds · 2023–2026
▶$13.2MraisedMay 2026 · 62 investors · BiotechnologyRule 506(b)
▶$13.2MraisedMay 2026 · 62 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Balamurali K. AmbatiExecutive Officer, Director
- Jayakrishna AmbatiExecutive Officer, Director
- Chaniyilparampu N. RamchandDirector
- Babur B. LateefDirector
- Napoleone FerraraDirector
- Offering amount
- $13.2M
- Amount sold
- $13.2M
- First sale
- Feb 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.5MraisedMar 2025 · 27 investors · Other Health CareRule 506(b)
▶$2.5MraisedMar 2025 · 27 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Balamurali AmbatiDirector
- Joon LeeDirector
- Napoleone FerraraDirector
- Paul AshtonExecutive Officer, Director
- Jayakrishna AmbatiDirector
- Mary WeberDirector
- Offering amount
- $10M
- Amount sold
- $2.5M
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.8MraisedJan 2024 · 24 investors · Other Health CareRule 506(b)
▶$3.8MraisedJan 2024 · 24 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Joon LeeDirector
- Paul AshtonExecutive Officer, Director
- Jayakrishna AmbatiDirector
- Balamurali AmbatiDirector
- Mary WeberDirector
- Napoleone FerraraDirector
- Offering amount
- $3.8M
- Amount sold
- $3.8M
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
UPMCUPMC is a regional healthcare provider that invests in community health through charity care, free and subsidized health programs, and support for seniors, veterans, and food-insecure populations.
Companies working in the same space as Inflammasome Therapeutics.
Frequently asked questions
- What does Inflammasome Therapeutics do?
- Inflammasome Therapeutics develops treatments for degenerative diseases including Alzheimer's disease, multiple sclerosis, macular degeneration, and Parkinson's disease. Its approach targets inflammasome activation as a mechanism to treat these conditions.
- Who founded Inflammasome Therapeutics?
- Inflammasome Therapeutics was founded by Paul Ashton, Jayakrishna Ambati.
- How much funding has Inflammasome Therapeutics raised?
- Inflammasome Therapeutics has disclosed $19.4M raised across 3 rounds.
- Where is Inflammasome Therapeutics headquartered?
- Inflammasome Therapeutics is headquartered in Newton, US.